As shown in Figure 2C, CD45+CD4+CD25+FRδ+ cells (i.e., Tregs) specifically captured the Ral-S0456 in a manner that was readily competed with excess Ral-glucosamine, i.e. confirming that the tumor Tregs could indeed bind raltitrexed. This evidence concerns the gene CD4 and neoplasm.